SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Menezes Falcão, L.
Right arrow Articles by van Zwieten, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menezes Falcão, L.
Right arrow Articles by van Zwieten, P. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction

Luiz Menezes Falcão

University Hospital Santa Maria, Lisbon, Portugal, luis-falcao@ clix.pt

Fausto Pinto

University Hospital Santa Maria, Lisbon, Portugal

Luciano Ravara

University Hospital Santa Maria, Lisbon, Portugal

Peter Adriaan van Zwieten

University of Amsterdam, The Netherlands

Background

The prevalence of chronic heart failure (CHF) with systolic dysfunction is increasing. Plasma natriuretic peptides have been envisaged as diagnostic and predictive markers.

Aims

To investigate the relationship between the levels of B-type natriuretic peptide (BNP) and A-type natriuretic peptide (ANP) and the clinical and functional parameters of CHF in outpatients with CHF at baseline, compared with normal healthy controls; to find out the differences in a randomised controlled trial between patients treated with an angiotensin-converting enzyme (ACE) inhibitor, captopril, or an angiotensin receptor blocker (ARB), irbesartan. These differences were assessed throughout the six-month treatment period and at the sixth month.

Methods Plasma BNP (pmol/L) and ANP (pmol/L) were

determined in 68 hypertensive patients with dilated cardiomyopathy, NYHA class III-IV and ejection fraction (EF) <40%, and in 26 normal controls. Statistical analysis for BNP and ANP was done by Student's t-test. The patient group was randomly subdivided into two subgroups of 34 patients, each treated with either an ARB, irbesartan, or an ACE inhibitor (ACE-I), captopril. BNP and ANP were measured in both subsamples and correlated with clinical, functional and neurohormonal parameters throughout a follow-up period of six months and at the sixth month.

Results

The mean EF in the patient sample was 33.43±6.52% and in the controls was 61.96 ±3.53% (p=0.000). The mean BNP (pmol/L) in patients was 44.78±54.36 and in the controls was 7.12±8.28 (p=0.000) and the mean ANP (pmol/L) was 30.32±25.97 in patients and 11.18±7.92 in controls (p=0.000). A statistically significant difference was found between patients and healthy controls. Significant correlations were found between natriuretic peptides and EF. Between the baseline phase and the sixth month, BNP and ANP decreased significantly in the ARB group. At the sixth month, both BNP and ANP were lower in the ARB group. Evidence of clinical benefit was found with both ARB or ACE-I treatment throughout the six months, with patients moving from classes III and IV to class II NYHA. Improvement of EF was also found, with transition of patients with lower EF (even <30%) to higher values. EF was higher in the ARB group at the sixth month.

Conclusions

BNP and ANP can be useful diagnostic tools in hypertensive CHF patients with moderate-to-severe LV dysfunction. The decrease in BNP and ANP in the ARB group throughout six months, as well as the lower value at the sixth month, suggest a prognostic value of these parameters.

Key Words: A-type natriuretic peptide • B-type natriuretic peptide • ET-1 • heart failure • diagnosis • left ventricular dysfunction

References

  • Pitt B., Poole-Wilson P.,Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN, Johnson GR, Shabeta R. et al. Ejection fraction, peak exercise oxygen consumption. Cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87:VI-5-VI-16.[Medline] [Order article via Infotrieve]
  • Kelly TL, Cremo R., Nelson C., Shabeiti R. Prediction of outcome in late stage cardiomyopathy. Am Heart J. 1990;119:1111-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fuster V., Gersch BJ, Guiliani ER, Tajik AL Brandenburg RO, Frye RL The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:52-31.
  • Dargie HJ, Cleland JGF, Leeckie BJ et al. Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation 1987;75:IV8-IV107.
  • Lee TH, Hamilton MA, Stevenson LW et al. Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol 1993;72:672-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wong M., Johnson G., Shahetai R. et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure: Veterans Affairs Cooperative Studies V-HeFT I and II. Circulation 1993;87;V165-V170.
  • Keogh AM, Baron DW, Hickie JB Prognostic guides in patients with idiopathic or ischaemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990:65:903-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haher HL, Leavy JA, Kessler PD et al.The erythrocyte sedimentation rate in congestive heart failure. N Engl J Med 1991;324:353-8.[Abstract]
  • Haywood GA, Rickenbacher PR,Tindale PT et al.Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria. Heart 1996;75:455-62.[Abstract/Free Full Text]
  • Komajda M.,Jais IP, Reeves B. et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 1990;11:824-31.[Abstract/Free Full Text]
  • Rickenbacher PR, Trindade PT, Haywood GA et al. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. J Am Coll Cardiol 1996;27:1192-7.[Abstract]
  • Adams KF, Dunlap SH, Sueta CA et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996;28:1781-8.[Abstract]
  • Gradman A., Deedwania P., Cody R. et al. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol 1989;14:546-70.
  • Anker SD, Ponikowski P., Warney S. et al. Wasting as independent risk factor of mortality in chronic heart failure. Lancet 1997;349:1050-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Parameshwar J., Keegan J., Sparrow J. Predictors of prognosis in severe chronic heart failure. Am Heart J 1992; 123:421-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Szabo BM, van Veldhuisen DJ, van der Veer N., Brouwer J., De Graeff PA, Crijns HY Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischaemic dilated cardiomyopathy. Am J Cardiol 1997;79:978-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Madsen BK,Videbaek R. Stokholm H. et al. Prognostic value of echocardiography in 190 patients with chronic congestive heart failure. A comparison with New York Heart Association functional classes and radionuclide ventriculography. Cardiology 1996;87:250-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Curtiss C., Cohn JN, Vrobel T., Franciosa JA Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-76. 20. Anand IS, Ferrari R., Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC Edema of cardiac origin. Circulation 1989;80:299-305.[Abstract/Free Full Text]
  • Mc Donagh T., Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hara H., Oghira T., Shima J. et al. Plasma atrial natriuretic peptide level as an index for the severity of congestive heart failure. Clin Cardiol 1987;10:437-42.[Web of Science][Medline] [Order article via Infotrieve]
  • Lerman A., Gibbons RJ, Rodeheffer RJ et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left - ventricular dysfunction. Lancet 1993;341: 1105-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Francis GS, Benedict C., Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure.A substudy
  • of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9.[Abstract/Free Full Text]
  • Isnard R., Pousset F., Trochu J. et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000;86:417-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tsutamoto T., Wada A., Maeda K. et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.[Abstract/Free Full Text]
  • Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.[Abstract/Free Full Text]
  • Gottlieb SS, Kukin ML, Ahern D., P Racker M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.[Abstract]
  • Tsutamoto T., Maeda K., Hisanaga T. et al. Plasma brain natriuretic peptide concentration as a prognostic predictor in patients with symptomatic left ventricular dysfunction (Abstr). Circulation 1996;94:I-255.
  • Tsutamoto T., Wada A., Maeda K. et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799-807.[Abstract/Free Full Text]
  • Mc Donagh TA, Cunningham AD, Morrison CE et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001;86:21-6.[Abstract/Free Full Text]
  • Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlof G., Mark AL Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-19.[Abstract/Free Full Text]
  • Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure.NEnglJMed 1962;267:650-4. 34. Thomas JA, Marks BH Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-7.[Abstract/Free Full Text]
  • Rector TS, Olivari MT, Levine TB, Francis GS, Cohn JN Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 1987;114:148-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Francis GS, Goldsmith SR, Cohn JN Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J 1982;104:725-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Viquerat CE, Daly P., Swedberg K. et al. Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. Am J Med 1985;78:455-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ferrari R., Ceconi C., Curello S., Visioli O. The neuroendocrine and sympathetic nervous system in congestive heart failure. Eur Heart J 1998;19(Suppl F):F45-F51.[Web of Science][Medline] [Order article via Infotrieve]
  • Madeson BK, Keller N., Christiansen E., Christensen NJ Prognostic value of plasma catecholamines, plasma renin activity and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: comparison with clinical evaluation, ejection fraction and exercise capacity. Cardiac Failure uation, ejection fraction and exercise capacity. Cardiac Failure 1995;1:207-16.
  • Cohn J., Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23. 43. Benedict CR, Shelton B., Johnstone DE et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-7.[Abstract/Free Full Text]
  • Rockman HA, Juneau C., Chatterjee K., Rouleau J. Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1989;64:1344-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cowie MR, Struthers AD, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-53.
  • Tsutamoto T., Hisanaga T., Fukai D. Wada A., Maeda Y., Kinoshita M. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995;76:803-08.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AMTreatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Poole-Wilson PATailored treatment for heart failure: an emerging concept. Am Heart J 1999;138:1005-06.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Richardson AM, Doughty R., Nicholls MG et al. For the Australia - New Zealand Heart Failure Group. Neurohormonal predictors of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999;99:786-97.[Abstract/Free Full Text]
  • Murdoch DR, Mc Donagh TA, Byrne J. et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138:1126-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Benedict CR, Johnstone DE, Weiner DH et al. Relation of neurohormonal activation to clinical variables and degree of left ventricular dysfunction. J Am Coll Cardiol 1994;23:1410-20.[Abstract]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 5, No. 3, 121-129 (2004)
DOI: 10.3317/jraas.2004.028
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Menezes Falcão, L.
Right arrow Articles by van Zwieten, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menezes Falcão, L.
Right arrow Articles by van Zwieten, P. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement